TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26503383

Group type: EXPERIMENTAL
Intervention: Guided e-learning intervention for managers on work-related stress
Number of subjects: 424

Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Guided e-learning intervention for managers
Number of subjects: 424
Study: 23391763

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery and rt‐PA
Number of subjects: 118

Group type: COMPARATOR
Intervention: Surgical aspiration and rt‐PA
Number of subjects: 118

Group type: COMPARATOR
Intervention: Surgical aspiration only
Number of subjects: 118
Study: 21300377

Group type: EXPERIMENTAL
Intervention: Olanzapine plus sertraline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Olanzapine monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination of an antipsychotic and an antidepressant
Number of subjects: 0
Study: 19342609

Group type: EXPERIMENTAL
Intervention: Peripheral parenteral nutrition with thiamine (n=8)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Peripheral parenteral nutrition without thiamine (n=7)
Number of subjects: 15
Study: 17584563

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 313

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 313
Study: 15682973

Group type: EXPERIMENTAL
Intervention: Neonatal BCG vaccination
Number of subjects: 0
Study: 16084808

Group type: EXPERIMENTAL
Intervention: Gait trainer exercise with functional electric stimulation (GTstim)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Gait trainer exercise without stimulation (GT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Walking overground (WALK)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All groups (GTstim, GT, WALK)
Number of subjects: 45
Study: 10485530

Group type: EXPERIMENTAL
Intervention: Ketorolac ophthalmic drops 0.5% prescribed four times a day for at least 3 months
Number of subjects: 9
Study: 8934482

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection (2 ml containing 40 mg of triamcinolone acetonide + 4 ml of 1% lidocaine without epinephrine)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (6 ml of 1% lidocaine without epinephrine)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study: 1882910

Group type: EXPERIMENTAL
Intervention: sucralfate
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: omeprazole
Number of subjects: 21

Group type: COMPARATOR
Intervention: Maalox
Number of subjects: 21
Study: 6352169

Group type: EXPERIMENTAL
Intervention: Antabuse (50 to 200 mg daily for 6 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Antabuse
Number of subjects: 24
Study: 30657226

Group type: EXPERIMENTAL
Intervention: Gratitude diary
Number of subjects: 201

Group type: COMPARATOR
Intervention: Food diary
Number of subjects: 201
Study: 29045995

Group type: EXPERIMENTAL
Intervention: Carbohydrate‐electrolyte solution (CES)
Number of subjects: 7
Study: 26548549

Group type: EXPERIMENTAL
Intervention: Usual orphan care plus mentoring, financial education, and matched savings accounts
Number of subjects: 346

Group type: COMPARATOR
Intervention: Usual orphan care plus mentoring (Control)
Number of subjects: 346
Study: 24735962

Group type: EXPERIMENTAL
Intervention: FC plus subcutaneous alemtuzumab 30 mg on day 1 (FCA)
Number of subjects: 272

Group type: COMPARATOR
Intervention: FC (control)
Number of subjects: 272
Study: 22987879

Group type: EXPERIMENTAL
Intervention: Family-based intervention (dietary and physical/sedentary activities education, behavioral modification)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Information control (IC)
Number of subjects: 96
Study: 19488646

Group type: EXPERIMENTAL
Intervention: Levamisole (150mg three times a week for six months)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 24
Study: 17321952

Group type: EXPERIMENTAL
Intervention: n‐3 fatty acid supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study: 15279439

Group type: EXPERIMENTAL
Intervention: Manipulation of place and task (Experiment 1)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Place alone (Experiment 2)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Task alone (Experiment 3)
Number of subjects: 3
Study: 11575484

Group type: EXPERIMENTAL
Intervention: Written Decision Support Aid (DSA)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Computerized Decision Support Aid (DSA)
Number of subjects: 56

Group type: COMPARATOR
Intervention: No Decision Support Aid (DSA)
Number of subjects: 56
Study: 9696518

Group type: EXPERIMENTAL
Intervention: Lightbox treatment with 1500-2500 lux white light for 2 h in the morning for 6 days (n=34)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Dawn simulation treatment in their homes, with 60 or 90 min of light augmentation time to 100-300 lux for 2 weeks (n=27)
Number of subjects: 61
Study: 8024920

Group type: EXPERIMENTAL
Intervention: High-dose fentanyl anaesthesia
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low-dose fentanyl anaesthesia
Number of subjects: 12
Study: 29690959

Group type: EXPERIMENTAL
Intervention: Obtura II gutta‐percha with AH plus sealer
Number of subjects: 70

Group type: COMPARATOR
Intervention: Obtura II gutta‐percha with Sealapex sealer
Number of subjects: 70
Study: 29158726

Group type: EXPERIMENTAL
Intervention: Mineral glycinate complexes + 2 CENs (daily dose: 36 mg iron, 15 mg zinc, 2 mg copper, 2 g carnitine, 400 mg phosphatidylserine)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Mineral glycinate complexes + 2 CENs (1 g carnitine)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Mineral glycinate complexes + 2 CENs
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Generic minerals + CENs
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 26189886

Group type: EXPERIMENTAL
Intervention: New Nordic Diet (NND) served for lunch during the intervention period
Number of subjects: 834

Group type: COMPARATOR
Intervention: Control group (packed lunch)
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: New Nordic Diet (NND)
Number of subjects: 834
Study: 24179297

Group type: EXPERIMENTAL
Intervention: Social Cognitive Therapy (SCT)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Social Interaction (SI)
Number of subjects: 206
Study: 21173173

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg per os once daily for 5 days
Number of subjects: 90

Group type: COMPARATOR
Intervention: Clindamycin 300 mg per os four times daily for 5 days
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 90
Study: 18837976

Group type: EXPERIMENTAL
Intervention: Isometric exercises
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Body scan
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 20
Study: 16448896

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Eprosartan (600 mg)
Number of subjects: 21
Study: 12883365

Group type: EXPERIMENTAL
Intervention: SRL172 + low-dose IL-2
Number of subjects: 32

Group type: COMPARATOR
Intervention: SRL172 alone
Number of subjects: 32
Study: 10701731

Group type: EXPERIMENTAL
Intervention: Glutamine suspension (16 g in 240 ml normal saline)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 17
Study: 9412131

Group type: EXPERIMENTAL
Intervention: Powdered microcrystalline cellulose dosed 5 g/day for three months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Powdered corn starch
Number of subjects: 50
Study: 8242128

Group type: EXPERIMENTAL
Intervention: Corticotrophin-releasing hormone (CRF) test (1 μg/kg body weight)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control saline study
Number of subjects: 22
Study: 3519041

Group type: EXPERIMENTAL
Intervention: High-dose alizapride (4 mg/kg X five doses)
Number of subjects: 62

Group type: COMPARATOR
Intervention: High-dose metoclopramide (2 mg/kg X five doses)
Number of subjects: 62
Study: 29494489

Group type: EXPERIMENTAL
Intervention: Galacto-oligosaccharide/polydextrose formula (PF)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Standard formula (SF)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Exclusive breastfeeding (BF)
Number of subjects: 201
Study: 26315810

Group type: EXPERIMENTAL
Intervention: Crushed ticagrelor 180 mg (2 tablets, semi-upright position)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Integral ticagrelor 180 mg (2 tablets, supine position)
Number of subjects: 20
Study: 24560995

Group type: EXPERIMENTAL
Intervention: Wavefront-guided LASIK
Number of subjects: 55

Group type: COMPARATOR
Intervention: Wavefront-optimized LASIK
Number of subjects: 55
Study: 21221678

Group type: EXPERIMENTAL
Intervention: Tetric-C
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Tetric-EC
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Gradia-DP
Number of subjects: 49
Study: 20070961

Group type: EXPERIMENTAL
Intervention: Rectal misoprostol (800 microg at the time of peritoneal incision)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Intravenous oxytocin infusion (after delivery of the neonate)
Number of subjects: 200
Study: 18788841

Group type: EXPERIMENTAL
Intervention: Flumazenil (0.5 mg or 1.0 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Midazolam (0.075 mg/kg)
Number of subjects: 0
Study: 16279150

Group type: EXPERIMENTAL
Intervention: Trials in 2002
Number of subjects: 494
Study: 12481161

Group type: EXPERIMENTAL
Intervention: Rabeprazole 40 mg
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 127

Group type: COMPARATOR
Intervention: Omeprazole 40 mg
Number of subjects: 127
Study: 10068575

Group type: COMPARATOR
Intervention: Amprenavir (1200 mg) alone
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Amprenavir with zidovudine (300 mg) plus lamivudine (150 mg)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Triple therapy (Amprenavir, zidovudine, and lamivudine)
Number of subjects: 92
Study: 7569287

Group type: EXPERIMENTAL
Intervention: Lactitol
Number of subjects: 10
Study: 2077509

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 6770760

Group type: EXPERIMENTAL
Intervention: Sodium valproate (30-60 mg/kg per day)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Phenobarbitone (3-6 mg/kg per day)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 64
Study: 30607983

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation applied to the quadriceps muscles (n=23)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group received electrical stimulation on the tibialis anterior muscle (n=22)
Number of subjects: 45
Study: 30511796

Group type: EXPERIMENTAL
Intervention: CMAC videolaryngoscope
Number of subjects: 80

Group type: COMPARATOR
Intervention: Truview Picture Capture Device
Number of subjects: 80
Study: 26876926

Group type: EXPERIMENTAL
Intervention: BLA activation during successful encoding of negative scenes in PTSD
Number of subjects: 22

Group type: COMPARATOR
Intervention: BLA activation during successful encoding of negative scenes in TEC
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Memory-related activity in the BLA
Number of subjects: 22
Study: 24026542

Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (usual diabetes regimen)
Number of subjects: 12
Study: 22875559

Group type: EXPERIMENTAL
Intervention: Integrative care
Number of subjects: 11

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 11
Study: 21121833

Group type: EXPERIMENTAL
Intervention: TAC (docetaxel, doxorubicin, and cyclophosphamide)
Number of subjects: 1060

Group type: COMPARATOR
Intervention: FAC (fluorouracil, doxorubicin, and cyclophosphamide)
Number of subjects: 1060

Group type: EXPERIMENTAL
Intervention: TAC
Number of subjects: 1060

Group type: COMPARATOR
Intervention: FAC
Number of subjects: 1060
Study: 17970229

Group type: EXPERIMENTAL
Intervention: Skin prick tests (SPTs) for sensitization to wheat flour
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Skin prick tests (SPTs) for sensitization to oat, barley, and rye flour
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation analysis of atopy with specific sensitization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation analysis of specific sensitization with age, sex, working hours, working years, smoking status, and pack/years
Number of subjects: 0
Study: 16232370

Group type: EXPERIMENTAL
Intervention: CSII (Continuous Subcutaneous Insulin Infusion) in group CSII-1
Number of subjects: 90

Group type: COMPARATOR
Intervention: Multiple Injections (MI) in group MI-1
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: CSII in group CSII-2
Number of subjects: 90

Group type: COMPARATOR
Intervention: Comparison of CSII-1 vs. MI-1 and CSII-2
Number of subjects: 90
Study: 12198064

Group type: COMPARATOR
Intervention: saline (Group 1; n = 13)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: ropivacaine 0.5% (Group 2; n = 13)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: ropivacaine 0.5% plus clonidine 7.5 microg/mL (Group 3; n = 13)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: ropivacaine 0.5% (Group 2)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: ropivacaine 0.5% plus clonidine 7.5 microg/mL (Group 3)
Number of subjects: 39
Study: 10438346

Group type: EXPERIMENTAL
Intervention: Lamivudine (150 mg 2x/day)
Number of subjects: 1790

Group type: EXPERIMENTAL
Intervention: Lamivudine (150 mg 2x/day) plus loviride (100 mg 3x/day)
Number of subjects: 1790

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1790

Group type: EXPERIMENTAL
Intervention: Lamivudine arms
Number of subjects: 1790
Study: 7784415

Group type: EXPERIMENTAL
Intervention: Isradipine (5 mg for 8 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (for 8 days)
Number of subjects: 20
Study: 2184659

Group type: EXPERIMENTAL
Intervention: Valine, isoleucine, and leucine mixture
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control mixture
Number of subjects: 16
Study: 7294077

Group type: EXPERIMENTAL
Intervention: Corticosteroids (betamethasone)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Expectant management (EM group)
Number of subjects: 160
Study: 29787472

Group type: EXPERIMENTAL
Intervention: PF-06372865
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study: 27102506

Group type: EXPERIMENTAL
Intervention: MRA regimen with potassium canrenoate (200 mg IV bolus) followed by spironolactone (25 mg once daily for 6 months)
Number of subjects: 1603

Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 1603

Group type: EXPERIMENTAL
Intervention: MRA regimen
Number of subjects: 1603
Study: 23981186

Group type: EXPERIMENTAL
Intervention: Insulin pump therapy with a bolus calculator
Number of subjects: 27

Group type: COMPARATOR
Intervention: Multiple daily injection therapy
Number of subjects: 27
Study: 21633878

Group type: EXPERIMENTAL
Intervention: Dialysis center characteristics (dieticians' fulltime-equivalent, type of dialysis center)
Number of subjects: 570
Study: 20091042

Group type: EXPERIMENTAL
Intervention: Vagal nerve stimulation
Number of subjects: 135
Study: 18450408

Group type: EXPERIMENTAL
Intervention: Informational support
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Emotional support
Number of subjects: 71

Group type: COMPARATOR
Intervention: Paternalism
Number of subjects: 71

Group type: COMPARATOR
Intervention: Clarification
Number of subjects: 71

Group type: COMPARATOR
Intervention: Participation
Number of subjects: 71
Study: 16167290

Group type: EXPERIMENTAL
Intervention: 0.2% sodium naproxen, administered three times a day for 14 days
Number of subjects: 328

Group type: COMPARATOR
Intervention: 0.1% diclofenac, administered three times a day for 14 days
Number of subjects: 328
Study: 12868207

Group type: EXPERIMENTAL
Intervention: Ultrasonic vibration applied to the top of each post for thirty minutes
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ultrasonic vibration
Number of subjects: 60
Study: 10919419

Group type: EXPERIMENTAL
Intervention: Left hand
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Right hand
Number of subjects: 20
Study: 9384465

Group type: EXPERIMENTAL
Intervention: Ro 48-6791 (0.1-0.3-1 mg and 1-2-3 mg doses)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Midazolam (0.1 mg kg(-1))
Number of subjects: 10
Study: 1472793

Group type: EXPERIMENTAL
Intervention: PSK treatment
Number of subjects: 228

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 228
Study: 6610736

Group type: EXPERIMENTAL
Intervention: PRP-D vaccine (20 micrograms, two injections separated by one month)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PRP vaccine (20 micrograms, single injection)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PRP-D vaccine and PRP vaccine
Number of subjects: 0
Study: 30734018

Group type: EXPERIMENTAL
Intervention: Exercise group (standard care plus twice-weekly high-intensity aerobic exercise and resistance training)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 29063313

Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg intravenously every 2 weeks
Number of subjects: 168
Study: 26582269

Group type: EXPERIMENTAL
Intervention: Preparation counseling
Number of subjects: 637

Group type: COMPARATOR
Intervention: Preparation nicotine patch
Number of subjects: 637

Group type: COMPARATOR
Intervention: Preparation nicotine gum
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Intensive cessation in-person counseling
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Intensive cessation phone counseling
Number of subjects: 637

Group type: COMPARATOR
Intervention: 16 weeks of combination nicotine replacement therapy (nicotine patch + nicotine gum)
Number of subjects: 637

Group type: COMPARATOR
Intervention: 8 weeks of combination nicotine replacement therapy (nicotine patch + nicotine gum)
Number of subjects: 637
Study: 24612282

Group type: EXPERIMENTAL
Intervention: Methylprednisolone aceponate 0.1% ointment (MPA), applied once daily with ¼ fingertip unit for 5 days
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Methylprednisolone aceponate 0.1% ointment (MPA)
Number of subjects: 16
Study: 22049995

Group type: EXPERIMENTAL
Intervention: Interviewer-administered CPQ(8-10)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Interviewer-administered CPQ(11-14)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Self-administered CPQ(8-10)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Self-administered CPQ(11-14)
Number of subjects: 180
Study: 20546209

Group type: EXPERIMENTAL
Intervention: 0.4 microg/kg desmopressin
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 0.2 microg/kg desmopressin
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 18492739

Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Percutaneous chest drain insertion and urokinase
Number of subjects: 60
Study: 15969858

Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14757913

Group type: EXPERIMENTAL
Intervention: 48 mg betahistine
Number of subjects: 12
Study: 10354291

Group type: EXPERIMENTAL
Intervention: rhIGF‐I (100 microgram/kg desirable body weight, subcutaneously every 12 hours for up to 14 days)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: rhIGF‐I
Number of subjects: 72
Study: 8760703

Group type: EXPERIMENTAL
Intervention: Early induction group (induction the following morning after PROM)
Number of subjects: 1385

Group type: EXPERIMENTAL
Intervention: Late induction group (induction two days later)
Number of subjects: 1385

Group type: COMPARATOR
Intervention: Both groups (induction with oxytocin if no spontaneous contractions or if chorioamnionitis or fetal distress)
Number of subjects: 1385
Study: 2014943

Group type: EXPERIMENTAL
Intervention: Aspirin therapy (325 mg, alternate-day)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 333
Study: 6385507

Group type: EXPERIMENTAL
Intervention: 1000 mg cimetidine daily in four separate doses (q.i.d.)
Number of subjects: 149

Group type: COMPARATOR
Intervention: 400 mg cimetidine twice a day (b.i.d.)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Both regimens (q.i.d. and b.i.d.)
Number of subjects: 149
Study: 31819291

Group type: EXPERIMENTAL
Intervention: Household costs associated with P. vivax malaria treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Productivity losses as a household cost component
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health-care provider costs for routine care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost of administering a glucose-6-phosphate-dehydrogenase rapid diagnostic test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost of fluorescent spot test
Number of subjects: 0
Study: 29022844

Group type: EXPERIMENTAL
Intervention: Laser (photobiomodulation)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham (placebo)
Number of subjects: 42
Study: 26437144

Group type: EXPERIMENTAL
Intervention: Experiential avoidance
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: PTSD symptoms
Number of subjects: 184
Study: 24462489

Group type: EXPERIMENTAL
Intervention: Watching television while eating (TV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eating with a single snack type with TV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eating with TV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Eating without TV
Number of subjects: 0
Study: 22210481

Group type: EXPERIMENTAL
Intervention: Enhanced cognitive behavioral HIV risk reduction intervention (E‐CB)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Health promotion condition (HPC)
Number of subjects: 222